Miphic

Miphic is a Norwegian biotechnology company founded in 2022 that provides a mitochondrial screening platform for drug discovery, personalized medicine, and fundamental research. The company utilizes an imaging-based approach rather than bulk methods, which allows it to work with a low number of cells. Its platform is designed for high throughput, enabling the simultaneous screening of up to 96 conditions, including various drugs, metabolites, and patient samples. The process is further enhanced by machine learning, which the company uses for data analysis and the prediction of drug sensitivity.

The platform addresses the current clinical challenge of easily assessing mitochondrial metabolism, which is critical in areas such as cancer, neurodegenerative disease, diabetes, and aging. By providing diagnostic insights into mitochondrial function, Miphic helps clinicians identify potent drug candidates, optimize synergistic drug combinations, and personalize treatment choices based on specific patient cell samples. The Bergen-based company has received backing from investors including Techstars and the Creator Fund to support its development and operations.